NYSE · NVS
Healthcare · Drug Manufacturers - General
$140.37
Down-$0.55 (-0.39%)
Updated Sep 20, 2026, 8:28 AM
SID Score
5.9/10
Composite research score
Smart Money
58/100
Neutral
Price performance
1M range · 19 trading sessions · Daily adjusted prices
NVS closed at $140.37 after 19 trading sessions, down 11.17% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 18, 2026 | $140.87 | $141.15 | $139.60 | $140.37 | 2.25M |
| Sep 17, 2026 | $140.12 | $141.21 | $139.97 | $140.92 | 1.71M |
| Sep 16, 2026 | $140.58 | $141.46 | $138.28 | $138.70 | 1.89M |
| Sep 15, 2026 | $138.76 | $139.11 | $137.37 | $138.62 | 2.37M |
| Sep 14, 2026 | $141.64 | $141.64 | $138.99 | $138.99 | 2.48M |
| Sep 11, 2026 | $139.31 | $139.55 | $137.00 | $137.16 | 2.35M |
| Sep 10, 2026 | $138.76 | $139.43 | $137.46 | $137.48 | 2.42M |
| Sep 9, 2026 | $138.14 | $139.45 | $137.30 | $137.48 | 2.94M |
| Sep 8, 2026 | $139.94 | $140.46 | $137.115 | $137.70 | 10.27M |
| Sep 4, 2026 | $159.90 | $160.93 | $159.625 | $159.99 | 1.29M |
| Sep 3, 2026 | $164.48 | $164.48 | $161.42 | $163.09 | 2.45M |
| Sep 2, 2026 | $160.80 | $163.18 | $160.38 | $162.46 | 4.34M |
| Sep 1, 2026 | $162.15 | $163.57 | $160.21 | $161.25 | 4.33M |
| Aug 31, 2026 | $152.60 | $152.74 | $151.685 | $152.06 | 1.29M |
| Aug 28, 2026 | $154.51 | $154.565 | $152.77 | $153.81 | 1.17M |
| Aug 27, 2026 | $155.925 | $155.93 | $154.43 | $154.65 | 1.22M |
| Aug 26, 2026 | $158.41 | $159.19 | $157.44 | $157.54 | 1.47M |
| Aug 25, 2026 | $158.51 | $160.29 | $157.83 | $159.98 | 998.18K |
| Aug 24, 2026 | $157.12 | $158.46 | $156.77 | $158.02 | 801.26K |
The latest Smart Investors Daily articles mentioning NVS.
NVS research
Company profile and research snapshot.
Novartis develops and manufactures innovative drugs. Key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 14, 2026 | TD COWEN | Hold | — |
| Jul 13, 2026 | ROTHSCHILD & CO REDBURN | Sell | — |
| Jul 13, 2026 | BERENBERG | Hold | — |
| Jul 9, 2026 | ARGUS RESEARCH CORPORATION | Buy | — |
| Jun 30, 2026 | INTESA SANPAOLO EQUITY RESEARCH | Buy | — |
No generated briefing is available yet.
Yahoo · Sep 18, 2026
WINNIPEG, MB / ACCESS Newswire / September 18, 2026 / (GSS-TSX.V)(GSR-Frankfurt/Freiverkehr & Xetra) (the "Company" or "Gossan") is pleased to announce that the Board of Directors has appointed Kevin Norberg as interim Chief Executive Officer and Director, effective September 18, 2026.
Yahoo · Sep 18, 2026
The global theranostics market is set for significant growth through 2036, driven by precision medicine, rising cancer prevalence, molecular imaging advances and targeted radiopharmaceutical therapies. Oncology leads adoption, while therapeutic agents and radiotheranostics are key growth segments. North America holds the largest market share, with Asia-Pacific forecast to grow fastest. The report analyses market trends, technologies, applications, regional opportunities and leading companies, in
Yahoo · Sep 18, 2026
If approved, Cosentyx (secukinumab) will be first IL-17A inhibitor licensed in Europe for adults with polymyalgia rheumatica (PMR), providing new treatment option after steroids¹Recommendation based on data showing Cosentyx doubled sustained remission rates and delivered steroid sparing effects vs placebo; safety was consistent with established Cosentyx profile²Despite being a common inflammatory rheumatic disease in people over 50, there are limited advanced treatments for PMR; extended use of
Benzinga · Sep 18, 2026
https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-cosentyx-vr-0000326984_en.pdf
Interpretive context generated from the platform’s current data sources.
Novartis AG shares have experienced notable downward pressure in recent months, with the stock trading at $140.37, per SID market data. The stock has declined 8.82% over the past month and 6.60% over the trailing three-month period, though it still maintains a positive 14.28% return on a one-year basis. NVS is currently trading well below both its 50-day moving average of $152.74 and its 200-day moving average of $149.99, indicating sustained bearish technical momentum. The 14-day relative strength index stands at 34.4, approaching oversold territory below the conventional 30 threshold. Novartis carries a beta of 0.438, according to Massive/Polygon data, reflecting significantly lower volatility relative to the broader market. Average daily trading volume registers at approximately 1.65 million shares, while the company's market capitalization stands at roughly $259 billion, positioning it among the largest global pharmaceutical firms.
Novartis AG currently trades at a price-to-earnings ratio of 18.18, per SID market data, which sits within a reasonable range for large-cap healthcare companies. The negative PEG ratio of -0.79, according to SEC filings, suggests analysts are modeling a contraction in earnings growth, warranting further scrutiny of forward estimates. The company's price-to-book ratio stands at 5.90, reflecting a significant premium over book value that is characteristic of pharmaceutical firms with substantial intangible assets and intellectual property portfolios. On the income return side, Novartis offers a dividend yield of approximately 3.31%, providing meaningful income relative to the broader healthcare sector average. This yield has effectively increased as the stock price has declined over the past month. The current valuation metrics position Novartis as a moderately valued large-cap pharmaceutical name with an attractive income component for yield-focused investors within the healthcare space.
Novartis AG registers a composite smart money score of 58 out of 100, reflecting a neutral overall signal, per SID market data. Institutional activity represents the strongest component at 21.0 out of 25, indicating robust participation and continued allocation from major fund managers. According to 13F institutional filings, this elevated score suggests sustained confidence among large asset managers despite recent price weakness. Insider activity scores 12.5 out of 25, representing a middling level of corporate insider transactions as reported in SEC Form 4 filings. Dark pool activity records a score of 12.0 out of 25, indicating moderate levels of off-exchange block trading. Congressional trading activity registers at 12 out of 25, showing limited but present legislative trading interest. The divergence between strong institutional conviction and more muted insider and dark pool signals creates a mixed profile. The neutral composite reading suggests no pronounced directional bias from sophisticated market participants at the current price level of $140.37.
Novartis AG delivered mixed recent earnings results, according to company earnings reports. In the most recently reported quarter, the company posted earnings per share of $2.41 against analyst estimates of $2.16, representing a positive surprise of $0.25 or approximately 11.6%. However, the prior quarter saw a miss, with actual EPS of $1.99 falling short of the $2.07 consensus estimate by $0.08. Looking ahead, per analyst estimates, the upcoming quarter carries a consensus EPS projection of $2.10, with the following quarter estimated at $2.13. These forward estimates suggest analysts anticipate sequential earnings growth through the next two reporting periods. The next scheduled earnings report is expected on or around May 1, 2026. The pattern of alternating beats and misses introduces uncertainty around execution consistency, though the magnitude of the most recent beat substantially exceeded the prior shortfall, demonstrating underlying earnings power.
Wall Street analyst sentiment on Novartis AG remains divided, per SID consensus data. In the most recent action on July 14, 2026, TD Cowen maintained a Hold rating, while Berenberg also reiterated its Hold stance on July 13. Rothschild & Co Redburn maintained a Sell rating on the same date, representing the most bearish coverage among recent reports. On the bullish side, Argus Research Corporation upgraded NVS to Buy from Hold on July 9, 2026, marking the only rating change among recent coverage actions, per Wall Street analyst reports. Intesa Sanpaolo Equity Research reiterated its Buy rating on June 30. Of the five most recent analyst actions, two firms rate NVS as Buy, two maintain Hold ratings, and one carries a Sell recommendation. This distribution reflects a lack of consensus directional conviction, aligning with the stock's current technical positioning near oversold levels at an RSI of 34.4 while trading approximately 8.1% below its 50-day moving average.
The latest Smart Investors Daily articles mentioning NVS.
